Treating erectile dysfunction in renal transplant recipients

Drugs

Volumn 67, Issue 7, 2007, Pages 975-983

  Barry, John M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMITRIPTYLINE; AMPHETAMINE; CORTICOSTEROID; CYCLOSPORIN A; HISTAMINE H3 RECEPTOR ANTAGONIST; LEVODOPA; METHYLDOPA; OPIATE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; TACROLIMUS; TESTOSTERONE; VANCOMYCIN; VARDENAFIL;

CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GRAFT RECIPIENT; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; PATHOPHYSIOLOGY; PENIS PROSTHESIS; PRIAPISM; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT PLANNING;

ALPROSTADIL; HUMANS; IMPOTENCE; KIDNEY TRANSPLANTATION; MALE; PAPAVERINE; PENILE ERECTION; PENILE PROSTHESIS; PHOSPHODIESTERASE INHIBITORS; PSYCHOTHERAPY; VASODILATOR AGENTS;

EID: 34248336643     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767070-00003     Document Type: Review

References (33)

1. Rebollo P, Ortega F, Valdes C, et al. Influence of erectile dysfunction on health related quality of life of male kidney transplant patients. Int J Impot Res 2004; 16: 282-7
2. Malavaud B, Rostaing L, Rischmann P, et al. High prevalence of erectile dysfunction after renal transplantation. Transplantation 2000; 69: 2121-4
3. Lasaponara F, Paradiso M, Milan MG, et al. Erectile dysfunction after kidney transplantation: our 22 years of experience. Transplant Proc 2004; 36: 502-4
4. Russo D, Musone D, Alteri V, et al. Erectile dysfunction in kidney transplanted patients: efficacy of sildenafil. J Nephrol 2004; 17: 291-5
5. Feldmann HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
6. Christ GJ, Lue T. Physiology and biochemistry of erections. Endocrine 2004; 23: 93-100
7. Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol and Med 2006; 231: 154-65
8. Barry JM. Male sexuality in renal transplant recipients. Transplant Immunol News 2000; 16: 7-13
9. El-Bahnsawy MS, El-Assmy A, Dawood A, et al. Effect of the use of internal iliac artery for renal revascularization on penile vascularity and erectile function: a prospective study. J Urol 2004; 172: 2335-9
10. Gittes RF, Waters WB. Sexual impotence: the overlooked complication of a second renal transplant. J Urol 1979; 121: 719-20
11. Karacan I. Clinical value of nocturnal erection in the prognosis and diagnosis of impotence. Med Aspects Hum Sex 1970; 4: 27-34
12. Thase ME, Reynolds CF, Jennings JR, et al. Diagnostic performance of nocturnal penile tumescence studies in healthy, dysfunctional (impotent), and depressed men. Psychiatry Res 1988; 26: 79-87
13. Barry JM, Blank BH, Boileau M. Nocturnal penile tumescence monitoring with stamps. J Urol 1980; 15: 171-2
14. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocrine Pract 2002; 8: 440-56
15. Rhoden EL, Estrada C, Levine L, et al. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003; 170: 795-8
16. Fritsche L, Budde K, Dragun D, et al. Testosterone concentra-tions and sirolimus in male renal transplant patients. Am J Transplant 2004; 4: 130-1
17. Kantarci G, Sahin S, Uras AR, et al. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. Transplant Proc 2004; 36: 178-9
18. Wespes E, Wildschutz T, et al. The place for surgery for vascular impotence in the third millennium. J Urol 2003; 170: 1284-6
19. Düsing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65 (6): 773-86
20. Sharma RK, Prasad N, Gupta A, et al. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis 2006; 48: 128-33
21. Barrou B, Cuzin B, Malavaud B, et al. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 411-7
22. Prieto Castro RM, Anglada Curado FJ, Regueiro Lopez JC, et al. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. Br J Urol Int 2001; 88: 241-3
23. Cofan F, Gutierrez R, Beardo P, et al. Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction. Nefrologica 2002; 22: 470-6
24. Zhang Y, Guan DL, Ou TW, et al. Sildenafil citrate treatment for erectile dysfunction after kidney transplantation. Transplant Proc 2005; 37: 2100-3
25. Christ B, Brockmeier D, Hauck E, et al. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. Urology 2001; 58: 589-93
26. Rostaing L, Tran-Van T, Ader JL. Increased glomerular filtration rate in kidney transplant recipients who take sildenafil. N Engl J Med 2000; 342: 1679-80
27. Demir E, Balal M, Paydas S, et al. Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. Transplant Proc 2006; 38: 1379-81
28. Mansi MK, Alkhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159: 1927-30
29. Kim SC, Chang IH, Jeon HJ. Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 year. Br J Urol Int 2003; 92: 277-80
30. Abouseif SR, Breza J, Ruud JL, et al. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates. J Urol 1989; 142: 403-8
31. Levine SB, Althof LA, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54-7
32. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intra-cavernous alprostadil afladex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized crossover. Urology 2000; 55: 109-13
33. Cuellar DC, Sklar GN. Penile prosthesis in organ transplant recipient. Urology 2001; 57: 138-41